CANPOLAND S.A.

What CANPOLAND S.A. does

CanPoland S.A. (CanPoland Spółka Akcyjna) is a privately held Polish pharmaceutical company founded in 2018 and headquartered in Łódź, operating in the medical cannabis and pharmaceutical repackaging sectors. Its core activities are the distribution of medical marijuana and rare medicines to Poland's largest pharmacy networks and pharmaceutical wholesalers, GMP-certified secondary packaging (repackaging) of sterile, non-sterile, and controlled substances for EU parallel import transactions, and comprehensive pharmaceutical regulatory registration services. CanPoland holds a Wholesale Distribution Authorization, a controlled-substances trading permit covering narcotic groups I-N to IV-N and psychotropic groups II-P to IV-P, and a GMP certificate valid three years from 2022.

The company runs a vertically integrated model spanning import and distribution, planned domestic cultivation and primary production of medical marijuana flowers and oils using an in-house designed production line, and direct patient care via its subsidiary CanPoland Clinics — a network of medical centers (first location opened in Warsaw in Q3 2021) offering neurology, oncology, urology, and pain management consultations plus telemedicine. A joint venture, The Health Company Poland Sp. z o.o., was formed in 2020 with Canadian investor ICC to control the cannabis supply chain from R&D and cultivation through processing to B2B and B2C sale via the HempCloud platform. The company commercializes a standardized Cannabis extractum normatum (THC 2%, CBD ≤1%, 30ml, priced 600-650 PLN) through Polish pharmacies with 24-hour nationwide delivery. Equipment capabilities include a FARMALINE packaging line, Ishida combination scale, and SS4X+MTRX serialization device meeting 21 CFR Part 11, EU Annex 11, and EU Directive 2011/62/EU.

CanPoland's go-to-market combines enterprise B2B sales to pharmaceutical manufacturers and pharmacy networks, pharmacist education programs, regulatory services sold project-by-project, event-driven presence (Cannabis Business Europe 2021 keynote, Pharmacy EXPO Nadarzyn 2026), and direct-to-consumer telemedicine via clinics. Revenue is generated through transactional wholesale fees (medical marijuana and rare medicines), professional services fees (repackaging, regulatory registration), and product sales (Cannabis extractum, HempCloud consumer offerings). Pelion SA subsidiary TT Pharma holds a 30% strategic stake acquired in 2020; the company raised PLN 4.4 million via record-breaking equity crowdfunding in January 2021 and has been preparing a Warsaw Stock Exchange listing originally targeted for 2022.

Name

CANPOLAND S.A.

Legal name

CanPoland Spółka Akcyjna

Website

https://canpoland.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

11–50 employees

Short description

CanPoland S.A. is a Łódź-based Polish pharmaceutical company that distributes medical marijuana and rare medicines to Polish pharmacy networks, provides GMP-certified repackaging for EU parallel imports, runs regulatory registration services for pharma manufacturers, and operates cannabinoid therapy clinics through its CanPoland Clinics subsidiary.

Ownership category

akta.pro rank

Product category

Pharmaceutical Distribution

NAICS

Drugs and Druggists' Sundries Merchant Wholesalers (424210), Medicinal and Botanical Manufacturing (325411), Pharmaceutical Preparation Manufacturing (325412)

SIC

Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Medicinal Chemicals & Botanical Products (2833), Pharmaceutical Preparations (2834)

akta.pro primary industry

Cannabis Dispensary + Pharmacy/Clinical Model (Patient Services) (CRANAFAI)

akta.pro secondary industries

Specialty Pharmaceutical Distributors (HLAIAJAB), Generic ANDA/Regulatory Affairs & Submissions (HLAIABAJ)

Keywords

• Pharmaceutical wholesale distribution
• Medical cannabis distribution
• Pharmaceutical repackaging services
• GMP-certified manufacturing
• Medical cannabis clinics

Headquarters

HQ city

Lodz

HQ country

Poland

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Medical Marijuana Distribution (Import/Export): Distribution of unique and rare medicines, particularly medical marijuana. CanPoland is one of Poland's leading exporters of medical marijuana. They distribute to the biggest Polish pharmacy networks and pharmaceutical wholesalers. They educate pharmacists about distributed products.
2. Pharmaceutical Wholesale: Distribution of pharmaceutical products on Polish and European markets. The company provides high-quality services and is open to cooperation with domestic and foreign manufacturers for distribution of new products on the Polish market.
3. Pharmaceutical Repackaging Services: Repackaging services for pharmaceutical products, particularly for EU parallel import transactions. Services cover sterile and non-sterile products, batch certification, and repackaging of controlled substances (narcotic and psychotropic substances). GMP-certified secondary packaging.
4. Regulatory Registration Services: Comprehensive regulatory support for pharmaceutical companies including registration of pharmaceutical raw materials, documentation preparation, representation before the Office for Registration of Medicinal Products, MAH transfers, documentation audits, responses to regulatory inquiries, and post-registration updates.
5. Medical Cannabis Product Sales (via CanPoland Clinics): Sale of Cannabis extractum normatum THC 2%, CBD ≤1%, 30ml through pharmacies and CanPoland Clinics network, serving patients with cannabinoid therapy. Telemedicine services also provided.
6. Medical Marijuana Production: Upcoming full production line for medical marijuana pharmaceutical products in flower and oil forms, based on machine designed exclusively by CanPoland.

Pricing tiers

Go-to-market motion4 records

Distribution channels5 records

Marketing channels6 records

Core offering

CanPoland S.A. is a Polish pharmaceutical company that distributes unique and rare medicines including medical marijuana to Polish pharmacy networks and pharmaceutical wholesalers, provides GMP-compliant secondary packaging and repackaging services for EU parallel import transactions, supplies standardized Cannabis extractum normatum (THC 2%, CBD ≤1%) to patients via pharmacies, operates a network of CanPoland Clinics providing cannabinoid therapy consultations (neurology, oncology, urology, pain management) plus telemedicine, and offers pharmaceutical regulatory registration services.

Product overview

CanPoland S.A. is a Polish pharmaceutical company operating on the medical cannabis market with a vertically integrated business model. The core product portfolio consists of Cannabis extractum normatum THC 2% (a standardized oil extract for sublingual administration), supported by distribution and international trade of medical marijuana, GMP-certified repackaging services for parallel imports, and an upcoming production line for medical marijuana flowers and oils. The company also operates CanPoland Clinics as a subsidiary network of medical facilities specializing in cannabinoid therapy, and provides pharmaceutical registration services. Equipment offerings include the FARMALINE Packaging Line, Ishida Combination Scale, and SS4X+MTRX Serialization Device. The portfolio is complemented by the CanPoland Knowledge Base educational platform.

Differentiator

Problem solved

Functional benefit

Brands

• Cannabis extractum normatum THC 2%, CBD ≤ 1%, 30ml CANPOLAND: Standardized cannabis oil extract for sublingual/oral administration, containing 600mg THC total (20mg per 1ml), derived from Sativa-Indica hybrid (70% Sativa, 30% Indica) Cairo strain.
• HempCloud (The Health Company Poland)

Products and services

• Cannabis extractum normatum THC 2%, CBD ≤1%, 30ml CANPOLAND

Quantifiable outcome

• 4.4 million PLN raised in 11 minutes from 576 investors (January 2021), breaking national crowdfunding record
• +3 more outcomes

Named customers4 records

Segments5 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Three partnerships are on record, tiered core.

• The Health Company Poland Sp. z o.o.coreOthersJoint venture (subsidiary of CanPoland SA) with Canadian partner ICC for production and distribution of raw materials, semi-finished products, and finished products based on active cannabis substances. Operates the full supply chain from R&D and laboratories through cultivation and processing to direct sale on hempcloud.pl platform. Targets both B2B and consumer markets.
• CanPoland Clinics Sp. z o.o.coreOthersSubsidiary of CanPoland SA managing a network of medical clinics specializing in cannabinoid therapy. First clinic opened in Warsaw (al. KEN 103) in Q3 2021 with four specialties: neurology, oncology, urology, and pain management. Expansion planned to other major Polish cities. Also provides telemedicine services.
• Pharmacy Networks (Poland)coreChannel Partner/ Reseller/ DistributorMajor Polish pharmacy chains and pharmaceutical wholesalers that distribute CanPoland's medical marijuana and pharmaceutical products to end consumers. CanPoland also educates pharmacists about distributed products to support effective sales.

Scale indicators8 records

Recent moves10 records

Expansion highlights6 records

Broad incumbents

• Jazz Pharmaceuticals plc (GW Pharmaceuticals): Acquired GW Pharmaceuticals, the developer of Sativex and Epidiolex pharmaceutical cannabinoid medicines. Broad incumbent in pharmaceutical-grade cannabis products that competes with CanPoland at the prescriber and pharmacy level for cannabinoid therapy patient share.
• Curaleaf Holdings, Inc. Global cannabis company whose ET15 API is the source for CanPoland's Cannabis extractum normatum. Comparable as an upstream supplier and as a broader medical-cannabis player whose European footprint directly competes for the same Polish pharmacy and patient demand.
• Tilray Brands, Inc. Global cannabis leader with material European medical-cannabis footprint including Germany and Portugal operations. Direct comparable to CanPoland in pursuing EU pharmacy distribution of medical cannabis products and competing for similar regulatory permits.
• Canopy Growth Corporation: Global cannabis company with European medical cannabis operations through its Spectrum Therapeutics subsidiary. Comparable to CanPoland as a broad incumbent pursuing EU medical-cannabis distribution and patient-services channels in the same target markets.
• Pelion SA: One of the largest pharmaceutical distributors in Poland and CEE, and the parent of TT Pharma Sp. z o.o. which holds a 30% stake in CanPoland. Pelion is both strategic backer and a comparable incumbent in pharma wholesale distribution that CanPoland competes with for similar pharma manufacturer relationships.
• Aurora Cannabis Inc. Canadian-headquartered global cannabis company with established European medical cannabis operations. Competes with CanPoland for Polish and European pharmacy-channel distribution and for patient share in cannabinoid therapy.

Direct peers

• PHCANN International S.A. Polish medical cannabis company listed on WSE NewConnect. Direct competitor to CanPoland in the Polish medical cannabis distribution and patient-services space, with comparable regulatory positioning and target pharmacy/wholesale customers.

Others

• Eurofarma Polska: Polish pharmaceutical company involved in distribution and repackaging adjacent to CanPoland's GMP-certified secondary packaging service. Adjacent ecosystem participant — a potential CanPoland pharma-services customer or local competitor in pharmaceutical repackaging for parallel import.

Emerging players

• International Cannabis Corporation (ICC): Canadian cannabis investor that co-founded The Health Company Poland Sp. z o.o. joint venture with CanPoland. Comparable as an emerging cannabis company with European ambitions and partial overlap in cultivation/expertise that intersects with CanPoland's vertical-integration strategy.
• STENOCARE A/S: Danish medical cannabis company focused on Scandinavian and European pharmacy distribution. Comparable as an emerging European medical-cannabis player targeting adjacent geographic markets (Scandinavia) that CanPoland has flagged for expansion.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xtwitter.com/canpoland
• Facebookfacebook.com/canpoland
• LinkedInlinkedin.com/company/canpoland

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CANPOLAND S.A.